首页    期刊浏览 2024年11月24日 星期日
登录注册

文章基本信息

  • 标题:Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation
  • 本地全文:下载
  • 作者:Seok-Jo Kim ; Swarna Bale ; Priyanka Verma
  • 期刊名称:iScience
  • 印刷版ISSN:2589-0042
  • 出版年度:2022
  • 卷号:25
  • 期号:7
  • 页码:1-21
  • DOI:10.1016/j.isci.2022.104669
  • 语种:English
  • 出版社:Elsevier
  • 摘要:SummaryIntestinal dysbiosis is prominent in systemic sclerosis (SSc), but it remains unknown how it contributes to microvascular injury and fibrosis that are hallmarks of this disease. Trimethylamine (TMA) is generated by the gut microbiome and in the host converted by flavin-containing monooxygenase (FMO3) into trimethylamine N-oxide (TMAO), which has been implicated in chronic cardiovascular and metabolic diseases. Using cell culture systems and patient biopsies, we now show that TMAO reprograms skin fibroblasts, vascular endothelial cells, and adipocytic progenitor cells into myofibroblasts via the putative TMAO receptor protein R-like endoplasmic reticulum kinase (PERK). Remarkably, FMO3 was detected in skin fibroblasts and its expression stimulated by TGF-β1. Moreover, FMO3 was elevated in SSc skin biopsies and in SSc fibroblasts. A meta-organismal pathway thus might in SSc link gut microbiome to vascular remodeling and fibrosis via stromal cell reprogramming, implicating the FMO3-TMAO-PERK axis in pathogenesis, and as a promising target for therapy.Graphical abstractDisplay OmittedHighlights•Reprogramming mesenchymal progenitors into myofibroblasts by TMAO via PERK•FMO3 upregulation in SSc skin fibroblastsCell biology; Microbial metabolism; Microbiome.
国家哲学社会科学文献中心版权所有